Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 ROC (Joel Greenblatt) % is 46.19% as of Dec. 2025, which is 35% above its 10-year median of 34.34. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 84.43% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. WuXi XDC Cayman's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 46.19%.
The historical rank and industry rank for WuXi XDC Cayman's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:L74'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.56 Med: 34.34 Max: 60.38
Current: 43.9
During the past 6 years, WuXi XDC Cayman's highest ROC (Joel Greenblatt) % was 60.38%. The lowest was 9.56%. And the median was 34.34%.
STU:L74's ROC (Joel Greenblatt) % is ranked better than 84.43% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.835
vs STU:L74: 43.90
WuXi XDC Cayman's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 40.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
WuXi XDC Cayman ROC (Joel Greenblatt) % Related Terms
WuXi XDC Cayman ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L74 vs TMO, DHR, NTRA: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 46.19% mean?
WuXi XDC Cayman (STU:L74) has a ROC (Joel Greenblatt) % of 46.19% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WuXi XDC Cayman and its competitors. This is 35% above median its historical median of 34.34. Over the past decade, WuXi XDC Cayman's ROC (Joel Greenblatt) % has ranged from 9.56 to 60.38. According to the industry distribution chart, WuXi XDC Cayman ranks #33 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 15.6%.
Is WuXi XDC Cayman's ROC (Joel Greenblatt) % too high?
WuXi XDC Cayman's current ROC (Joel Greenblatt) % of 46.19% is 35% above median its 10-year median of 34.34. Over the past 10 years, this metric has ranged from a low of 9.56 to a high of 60.38. Based on the distribution chart, WuXi XDC Cayman ranks #33 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #33 out of 212 companies for ROC (Joel Greenblatt) %. This places WuXi XDC Cayman in the top 16% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own ROC (Joel Greenblatt) % has ranged from 9.56 to 60.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current ROC (Joel Greenblatt) % is 46.19%, which is 35% above median its own 10-year median of 34.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current ROC (Joel Greenblatt) % of 46.19%. The current ROC (Joel Greenblatt) % is 46.19%, which is 35% above median its 10-year median of 34.34. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current ROC (Joel Greenblatt) % is 46.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
